Showing results (91-100 of 682) with videos related to
Sort By:
Pageof 69
Anti-Cancer Agents in Medicinal Chemistry|May 16, 2012
JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?Fabio P S Santos, Srdan VerstovsekExpert Opinion on Pharmacotherapy|May 27, 2014
Efficacy of ruxolitinib for myelofibrosisFabio P S Santos, Srdan VerstovsekExpert Opinion on Investigational Drugs|September 29, 2009
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancerPrithviraj Bose, Howard OzerLeukemia Research Reports|August 27, 2013
Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML)Prithviraj Bose, Steven GrantF1000Research|November 21, 2017
Recent therapeutic advances in chronic lymphocytic leukemiaPrithviraj Bose, Varsha GandhiFaculty Reviews|March 15, 2021
Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitorsPrithviraj Bose, Varsha GandhiJournal of Clinical Medicine|June 27, 2015
Rational Combinations of Targeted Agents in AMLPrithviraj Bose, Steven GrantCase Reports in Hematology|August 9, 2014
Isolated gastric myeloid sarcoma: a case report and review of the literaturePankit Vachhani, Prithviraj BoseBlood Advances|April 22, 2021
Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNsLucia Masarova, Courtney D DiNardo, Prithviraj Bose, et al.Therapeutic Advances in Hematology|February 21, 2024
Interferons in the treatment of myeloproliferative neoplasmsPankit Vachhani, John Mascarenhas, Prithviraj Bose, et al.Pageof 69